Successful osimertinib rechallenge without concomitant corticosteroids after osimertinib-induced pneumonitis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Successful osimertinib rechallenge without concomitant corticosteroids after osimertinib-induced pneumonitis

Published:2024 Issue: Volume:49 Page:102029
ISSN:2213-0071
Container-title:Respiratory Medicine Case Reports
language:en
Short-container-title:Respiratory Medicine Case Reports

Author:

Ito Taisuke,Tsuchiya Kazuo^ORCID,Mori Rie,Akashi Takuro,Oyama Yoshiyuki,Ikeda Masaki

Publisher

Elsevier BV

Reference20 articles.

1. Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset;Ohe;Jpn. J. Clin. Oncol.,2019

2. Final safety and efficacy of erlotinib in the phase 4 POLARSTAR surveillance study of 10 708 Japanese patients with non-small-cell lung cancer;Gemma;Cancer Sci.,2014

3. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib;Ando;J. Clin. Oncol.,2006

4. Osimertinib for Japanese patients with T790M-positive advanced non-small-cell lung cancer: a pooled subgroup analysis;Hirashima;Cancer Sci.,2019

5. Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-cell lung cancer: AURA3 trial;Akamatsu;Cancer Sci.,2018

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3